Methods of treatment with a bioresorbable scaffold for neurologic drug delivery
AssigneeAbbott Cardiovascular Systems Inc.
InventorsTerry B. Mazer, Stephen D. Pacetti, Brenna H. Lord
Life of this patent
Estimating the term…
Abstract
Bioresorbable scaffolds and methods of treatment with such scaffolds for neurologic disorders including Parkinson's disease, Huntington's disease, Alzheimer's disease, and brain neoplasms are disclosed. The bioresorbable scaffold includes a bioresorbable body and an active agent or drug associated with the body for treating or ameliorating the neurological disorder. The bioresorbable scaffold is implanted in the neurological vasculature brain or brain tissue to provide localized delivery of the drug or active agent. Embodiments of the invention include scaffolds that are partially bioresorbable or completely bioresorbable.
Claims8
A method for delivering an active agent to a patient that is capable of rendering a pathogenic protein that causes a neurological disease in the central nervous system nonpathogenic, comprising:
- implanting a bioresorbable scaffold in the lenticulostriate branches of the middle cerebral artery upstream of the substantia nigra region or the basal ganglia of a patient in need of treatment or amelioration of Huntington's or Parkinson's disease, wherein the bioresorbable scaffold comprises an active agent,
- wherein the active agent is capable of rendering a pathogenic protein from the substantia nigra region or the basal ganglia that causes the disease nonpathogenic,
- wherein the active agent moves downstream from the implanted scaffold to come into contact with the pathogenic protein.
A method for delivering an active agent to a patient that is capable of rendering a pathogenic protein that causes a neurological disease in the central nervous system nonpathogenic, comprising:
- implanting a bioresorbable scaffold in the lenticulostriate branches of the middle cerebral artery upstream of the substantia nigra region or the basal ganglia of a patient with no symptoms of Huntington's disease, wherein the bioresorbable scaffold comprises an active agent, and
- wherein the active agent from the implanted scaffold moves downstream and comes into contact with a pathogenic protein from the substantia nigra region or the basal ganglia that causes Huntington's disease.
Dependencies are inferred from the claim text.